Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsAnton BUCHNER, Andreas Lammerich, Noa Avisar
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count, including neutropenia, in human patients that are less than 18 years old. The methods and compositions described herein include a fusion polypeptide comprising human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”).
Claims29
A method of treating or preventing neutropenia in a human subject comprising administering to a human subject exhibiting neutropenia or at risk of developing neutropenia 300 μg/kg to 670 μg/kg of recombinant human albumin-human granulocyte colony stimulating factor, wherein the human subject is less than 18 years old.
A method of decreasing the incidence of infection, as manifested by febrile neutropenia, in a human subject with a non-myeloid malignancy and receiving at least one myelosuppressive anti-cancer drug associated with a clinically significant incidence of febrile neutropenia, comprising administering to the subject 300 μg/kg to 670 μg/kg recombinant human albumin-human granulocyte colony stimulating factor, wherein the human subject is less than 18 years old.
Dependencies are inferred from the claim text.